Characterization of Exacerbations of Severe Eosinophilic Asthma on Mepolizumab Compared to Placebo

Poster No. 506 (A2671)

Presented at the American Thoracic Society International Conference, Dallas, TX, USA, May 17–22, 2019

Shrimanker R, Keene O, Bratton DJ, Yunne SY, Heaney LG, Pavord ID

PhD

Alarms

- Mepolizumab, a humanised monoclonal antibody, targets E- and has been shown to reduce exacerbations of severe eosinophilic asthma. 1
- We have previously shown, in an analysis of exacerbations occurring in 60 patients receiving mepolizumab or placebo, that exacerbations occurring on mepolizumab are associated with lower sputum eosinophil counts and lower decrements in symptom scores measured by the visual analogue scale (VAS) compared to placebo. 2
- We suggest that this might reflect a different, less corticosteroid responsive mechanism of exacerbation in patients treated with mepolizumab.

Methods

- We carried out a post-hoc comparison of exacerbations occurring during treatment with mepolizumab or placebo in three previously reported placebo-controlled trials. 1,3
- Diary card data was reviewed from the 3 studies involving 1743 patients with severe eosinophilic asthma; DREAM, a 52-week study of 3 doses of mepolizumab (75, 250 or 750 mg i.v. weekly) versus placebo; MUSC-3, a 32-week study of 2 doses of mepolizumab (75mg IV or 100mg i.c. weekly) versus placebo; and MUSC-4, a 24-week study of mepolizumab 100mg i.c. weekly versus placebo.
- All studies recruited patients with a history of 2 or more exacerbations in the previous year and evidence of eosinophilic airway inflammation.
- Patients completed a daily diary card including 6 point symptom score assessing asthma symptoms in the previous 24 hours (0 – no symptoms, 6 – worst symptoms) and a best-of-three morning peak expiratory flow (PEF) (recorded in L/min). Patient medication usage was recorded.
- Exacerbations were defined as worsening symptoms and/or respiratory infection that required rescue oral corticosteroids (OCS) for 3 or more days. Events with at least 20 days diary card data in the period 14 days prior to starting OCS (Day -14) to 14 days (Day 14) after starting OCS were included in the analysis.
- PEF and symptom score at each day was averaged across all included exacerbations. Unpaired t-tests were used to compare mean change from Day -14 at day of OCS start (Day 0) between treatment groups with no adjustment for within subject correlation of events. The latest value recorded prior to OCS start was used for patients with missing assessment at Day 0.

Results

- 741 study participants across the 3 studies had at least one exacerbation. Their demographics are shown in Table 1.

Table 1. Participant demographics – participants who experienced one or more exacerbations during this study

<table>
<thead>
<tr>
<th></th>
<th>Placebo (N=23)</th>
<th>Mepolizumab AEDS (N=50)</th>
<th>Mepolizumab OCS (N=50)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age (years)</td>
<td>49.3±15.1</td>
<td>49.2±12.0</td>
<td>49.2±13.1</td>
</tr>
<tr>
<td>Sex (% female)</td>
<td>211 (65%)</td>
<td>258 (77%)</td>
<td>259 (74%)</td>
</tr>
<tr>
<td>BMI (kg/m²)</td>
<td>28.4±8.5</td>
<td>29.1±6.1</td>
<td>29.1±6.1</td>
</tr>
<tr>
<td>Baseline Maintenance OCS Therapy</td>
<td>108 (33%)</td>
<td>146 (29%)</td>
<td>146 (29%)</td>
</tr>
<tr>
<td>Baseline PEF/Equivalent Dose (mg)</td>
<td>14.4 (11.4)</td>
<td>16.3 (12.7)</td>
<td>16.3 (12.7)</td>
</tr>
<tr>
<td>Exacerbations in previous year</td>
<td>12/34 (42%)</td>
<td>16/49 (30%)</td>
<td>16/49 (30%)</td>
</tr>
<tr>
<td>3</td>
<td>87 (27%)</td>
<td>96 (22%)</td>
<td>96 (22%)</td>
</tr>
<tr>
<td>4+</td>
<td>101 (31%)</td>
<td>154 (27%)</td>
<td>154 (27%)</td>
</tr>
<tr>
<td>Baseline Blood Eosinophil Count (G/L)</td>
<td>0.34 (1.0)</td>
<td>0.20 (1.1)</td>
<td>0.20 (1.1)</td>
</tr>
</tbody>
</table>

Note: shown as mean (SD) where otherwise specified.
** Geometric mean (big SD).

- 1026 exacerbations were included in the analysis. 476 occurred in 248 subjects on placebo treatment and 550 occurred in 338 subjects on mepolizumab treatment. 717 exacerbations were not analysed due to insufficient diary card data.
- The baseline participant age, sex, BMI, maintenance OCS use or maintenance OCS dose, and lung function measures were similar between placebo and mepolizumab treated groups. The blood eosinophil count tended to be higher in the placebo treated group.
- Exacerbations on placebo had a larger increase in daily symptom score compared to mepolizumab (0.8 points vs 0.0 points respectively; mean difference 0.6, 95% CI 0.0, 0.4, Figure 1a) at the time of starting OCS. Placebo treated exacerbations tended to return to baseline more completely quickly than mepolizumab treated exacerbations following OCS (Figure 1a).
- Exacerbations on placebo were associated with a larger drop in PEF compared to mepolizumab at the time of starting OCS (-21.8 vs -20.8 L/min; mean difference 1.0 L/min, 95% CI -0.23, 0.6, Figure 1b). The rate of decline prior to OCS initiation was greater in the placebo group compared to the mepolizumab group. Both mepolizumab and placebo groups returned to their baseline in a similar time and rate (Figure 1b).

Conclusions

- Our results add further evidence that exacerbations occurring on mepolizumab are different to those that occur on placebo.
- Exacerbations on mepolizumab are less severe in terms of falls in lung function as measured by PEF and a similar trend was seen for symptoms.
- Our results also support the suggestion that there may be a difference in recovery from these different episodes with a trend towards longer recovery to baseline in the mepolizumab group. This may be explained by a differential response to oral corticosteroid treatment in mepolizumab treated patients compared to placebo.

References


Acknowledgements

- This study was funded by GSK (NCT01449681, NCT01165056, NCT02081316).
- The presenting author, RS, declines any real or perceived conflicts of interest during the last 3 years in relation to this presentation. OK, DB & SY are GSK employees and shareholders. LH declines the following: Academic; Lead to the UK MRC Consortium on Stratified Medicine in Severe Asthma – Industrial Partners are Amgen, AstraZeneca, MedImmune, Novartis, Roche / Genentech, Genentech, and SmithKline Beecham. Ingehelm; prior grant project funded from Medimmune; Novartis UK; Roche / Genentech; and GlaxoSmithKline has taken part in Advisory Board / Lectures supported by Novartis, Roche / Genentech, GlaxoSmithKline, Teva. Thoracace and Vessco; has travel funding support to international respiratory meetings AstraZeneca, Chiesi, Novartis, Boehringer Ingelheim, Teva, and GlaxoSmithKline and has taken part in asthma clinical trials (GlaxoSmithKline/Siemhng Pugh, Siemens, Novartis, and Roche / Genentech) for which his institution was remuneration, IDP has received fees for speaking from Astra Zeneca, Boehringer Ingelheim, Novartis, and GlaxoSmithKline, Teva;
- Organising educational events from AstraZeneca and Teva, responsible for attending educational events with Novartis, and Boehringer Ingelheim; and for travel support from AstraZeneca, Chiesi, Novartis, Boehringer Ingelheim, Genentech, AstraZeneca, Teva, Chiesi and a research grant from Chiesi.
- Editorial support (in the form of poster layout and formatting) was provided by Laura Pointer, PhD of Pembroke Indict Ltd, UK, and was funded by GSK.

Table 1. Participant demographics – participants who experienced one or more exacerbations during this study

Figure 1. Changes in symptoms and PEF during an exacerbation

Figure 2. Baseline and exacerbation OCS dose

Image 2403x20 to 2460x77

**Respiratory Medicine Unit and Oxford Respiratory NHR Biomedical Research Centre University of Oxford, Oxford, UK; 1Clinical Statistics, GSK, Stockley Park, Uxbridge, Middlesex, UK; 2Clinical Development, GSK, Research Triangle Park, NC, USA; 3Centre for Experimental Medicine, School of Medicine, Dentistry and Biomedical Sciences, Queen’s University Belfast, Belfast, UK.**